PubMed
Dihexa, a small molecule that promotes new synapse formation, demonstrates cognitive enhancement
McCoy AT, Tan DCS, Tschemernjak A, et al. J Pharmacol Exp Ther. 2013
Compare
Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.
Last reviewed . By the PeptIQ team.
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 69% · Mixed 20% · Unfavorable overall 11%
Benefits users selected when logging a favorable or mixed check-in.
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Median bucket: 0.6–1 mg · Most common: 0.6–1 mg
Reports span 0.2–3 mg
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Among repeat reporters, 64% said they felt similar to their last entry, 43% more positive, and 19% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 26 days · Based on 175 repeat reporters
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 68% · Mixed 22% · Unfavorable overall 10%
Benefits users selected when logging a favorable or mixed check-in.
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Median bucket: 0.4–0.6 mg · Most common: 0.4–0.6 mg
Reports span 0.05–2 mg
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Among repeat reporters, 63% said they felt similar to their last entry, 36% more positive, and 18% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 16 days · Based on 29 repeat reporters
Published sources linked on the Dihexa and SLU-PP-332 wiki pages.
PubMed
McCoy AT, Tan DCS, Tschemernjak A, et al. J Pharmacol Exp Ther. 2013
PubMed
Benoist CC, Kawas LH, Zhu M, et al. J Pharmacol Exp Ther. 2011
ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
PubMed
Ho JK, Nation DA. Neuroscience and biobehavioral reviews. 2018
PubMed
Wright JW, Kawas LH, Harding JW. Progress in neurobiology. 2015
PubMed
Li Z, Wu Y, Wang C, et al. Nat Commun. 2023
PubMed
Billon C, Schoepke E, Avdagic A, et al. The Journal of pharmacology and experimental therapeutics. 2024
PubMed
Okda HE, Zhao P, Hayes M, et al. International journal of biological macromolecules. 2026